SYNTHETIC DEMONSTRATION — no real student or patient. Not a medical device.

Medication

Ozempic Cost: What It Is and How to Pay Less

Ozempic (semaglutide) lists at roughly $1,027 per pen without insurance — around $1,000 per month for most doses. With commercial insurance and Novo Nordisk's savings card, eligible patients pay as little as $25 per fill for up to 48 months. Uninsured patients may qualify for the NovoCare Patient Assistance Program, which provides the drug at no cost to those at or below 200% of the federal poverty level.

Written by Gale Editorial · grounded in the cited clinical sources below · Updated 2026-06-15. How we write.

Drug facts

Generic name:
semaglutide
Class:
GLP-1 receptor agonist
Brand names:
Ozempic
How it's taken:
subcutaneous injection (once weekly)

Talk to a clinician

Gale can match you with a clinician licensed in your state — the honest cost shown before you book.

Find care →

What Ozempic Costs Without Insurance

Ozempic (semaglutide injection) has a list price of approximately $1,027 per pen, which corresponds to roughly $1,000 per month for the most common maintenance doses 1. Novo Nordisk, the manufacturer, sets this as the wholesale acquisition cost — the price before any discounts, rebates, or insurance adjustments are applied.

For self-pay patients, Novo Nordisk introduced a direct pricing structure through mid-2026:

  • New self-pay patients: $199 per month for the first two fills (0.25 mg and 0.5 mg starter doses)
  • Established self-pay patients: $349 per month for doses up to 1 mg; $499 per month for the 2 mg dose 2

These self-pay prices apply when purchasing through the NovoCare Pharmacy or participating retail pharmacies without running through insurance. They represent a meaningful reduction from the list price, but are still a substantial ongoing expense — particularly since Ozempic is prescribed for chronic, long-term use.

Why Ozempic Is Expensive

Semaglutide is protected by a composition patent in the United States that analysts project will remain in force until approximately December 2031, with practical generic or biosimilar market entry unlikely before 2032–2033 once secondary formulation and device patents are considered 3. No generic Ozempic exists today, and biosimilar development timelines in the U.S. are long.

During the 2023–2025 period, Ozempic was listed on the FDA drug shortage list due to extraordinary demand. Compounding pharmacies legally produced compounded semaglutide during that window. The FDA removed semaglutide from its shortage list in February 2025 and enforced deadlines (April–May 2025) for 503A and 503B compounding pharmacies to wind down production 4. As of mid-2026, compounded semaglutide from most outsourcing facilities is no longer legally available, meaning patients are back to brand-name pricing unless they qualify for assistance programs.

Savings Card: $25 per Month with Commercial Insurance

Novo Nordisk's Ozempic Savings Program (sometimes called a copay card or savings card) can reduce out-of-pocket costs significantly for commercially insured patients:

  • Eligibility: Patients with commercial (private or employer-sponsored) insurance where Ozempic is a covered benefit
  • Cost: As little as $25 per monthly fill; $200 for a 2-month supply; $300 for a 3-month supply
  • Maximum savings: Up to $1,001 per year (approximately $100 per month in savings)
  • Duration: Valid for up to 48 months from activation 2
  • Exclusions: Patients on Medicare, Medicaid, Tricare, VA, or other government-funded plans are not eligible for this card

The savings card does not reduce the full list price — it functions as a manufacturer subsidy on top of an insurance copay. If a plan covers Ozempic as a Tier 3 or Tier 4 drug, the copay before the card can be $200–$400 per month; the card then reduces that copay to $25. For patients whose plan does not cover Ozempic at all, the card generally does not apply.

Enrollment is available at ozempic.com or by calling 1-866-696-4090.

Patient Assistance Program: Free Medication for Those Who Qualify

The NovoCare Patient Assistance Program (PAP) provides Ozempic at no cost to eligible individuals. Key criteria as of 2026 2:

  • Income threshold: Total household income at or below 200% of the federal poverty level (approximately $30,120 for a single-person household in 2026, based on HHS guidelines)
  • Insurance status: Must have Medicare Part D or no insurance; patients with private commercial insurance are not eligible for the PAP
  • Exclusions: Patients already covered by Medicaid, the Medicare Low Income Subsidy, or VA benefits are not eligible
  • Application: Online at novocare.com or by calling 1-866-310-7549; a healthcare provider must complete a portion of the application
  • Timeline: Applications are typically processed within 2 business days; medication arrives within 5 business days after approval

For Medicare beneficiaries whose income exceeds PAP thresholds, the Medicare Part D cap is a separate path: the Inflation Reduction Act limits Part D out-of-pocket spending to $2,000 per year starting in 2025, which meaningfully reduces annual exposure for those with coverage.

Does Insurance Cover Ozempic?

Coverage depends on the reason Ozempic is prescribed and the specific insurance plan.

For type 2 diabetes: Most commercial plans, Medicare Part D, and many state Medicaid programs cover Ozempic when prescribed for glycemic control. Prior authorization is common and typically requires documentation of a type 2 diabetes diagnosis. Some plans require a trial of metformin or other first-line agents before approving Ozempic 5.

For cardiovascular risk reduction: Ozempic carries FDA approvals beyond diabetes — it is indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and (as of January 2025) to reduce the risk of kidney disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease 1. Plans that follow FDA labeling may cover Ozempic on these indications as well.

For weight loss (off-label): Ozempic is not FDA-approved for weight loss — Wegovy is the approved weight-loss formulation of semaglutide at a higher dose. Most commercial plans and Medicare do not cover Ozempic when the diagnosis code reflects weight loss rather than diabetes or a covered cardiovascular indication.

Appealing a denial: Prior authorization denials are often reversed on first appeal when a clinician submits a letter of medical necessity documenting the indication, comorbidities, and, if required, prior therapy history. Including A1C levels and cardiovascular or kidney comorbidities in appeal documentation strengthens the case.

Clinical Context: What Ozempic Is Approved For

Understanding what Ozempic is approved to treat matters for coverage and cost conversations with insurers.

Ozempic (semaglutide 0.5 mg, 1 mg, and 2 mg) was first approved by the FDA on December 5, 2017 (NDA 209637) for glycemic control in adults with type 2 diabetes, used alongside diet and exercise 1. Its approved indications have since expanded:

  • Cardiovascular risk reduction (SUSTAIN-6): Ozempic reduces the risk of major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, nonfatal stroke) in adults with type 2 diabetes and established cardiovascular disease
  • Chronic kidney disease (FLOW trial, 2024): Ozempic 1 mg reduced the composite of major kidney outcomes, cardiovascular events, and death by 24% in adults with type 2 diabetes and CKD compared with placebo, published in the *New England Journal of Medicine* 6

These expanded indications mean more patients with type 2 diabetes may have insurable grounds for coverage beyond diabetes alone — a conversation worth having with the prescribing clinician before appealing an insurance denial.

A Note on the Cost Model at Gale

Gale's care model is designed around transparent, predictable costs. For patients exploring whether Ozempic is clinically appropriate — and working through insurance coverage or the NovoCare PAP — a clinician visit through Gale is priced at cost plus 15%, with the price shown before booking. There are no referral fees and no financial relationship with Novo Nordisk or any pharmacy network.

Gale does not prescribe medications; prescribing decisions rest with the clinician. Actual prices vary by pharmacy and plan and should be confirmed at point of sale.

Common questions

How much does Ozempic cost per month without insurance?

The Novo Nordisk list price for Ozempic is approximately $1,027 per pen. Self-pay pricing through Novo Nordisk's direct program is $199 per month for the first two starter-dose fills, then $349 per month for doses up to 1 mg and $499 for the 2 mg dose, as of mid-2026. These prices are subject to change.

Who qualifies for the $25 Ozempic savings card?

The Novo Nordisk savings card is available to patients with commercial (private or employer-sponsored) insurance where Ozempic is a covered benefit. It reduces the copay to as little as $25 per monthly fill for up to 48 months. Patients on Medicare, Medicaid, Tricare, or other government plans are not eligible.

Is there a free Ozempic program for low-income patients?

Yes. The NovoCare Patient Assistance Program provides Ozempic at no cost to uninsured patients or Medicare Part D beneficiaries whose total household income is at or below 200% of the federal poverty level. Applications are submitted at novocare.com; a healthcare provider must co-complete the form.

Does Medicare cover Ozempic?

Medicare Part D generally covers Ozempic when it is prescribed for type 2 diabetes, cardiovascular risk reduction, or kidney disease reduction — all FDA-approved indications. Coverage for weight loss alone is not included. Starting in 2025, the Inflation Reduction Act caps Part D out-of-pocket spending at $2,000 per year.

Can I still get compounded semaglutide to save money?

Compounded semaglutide was legally available from licensed pharmacies during the FDA-declared shortage, which was resolved in February 2025. Enforcement deadlines for compounding facilities passed in April–May 2025. As of mid-2026, large-scale compounding of semaglutide from 503B outsourcing facilities is no longer permitted under FDA rules, and access to compounded versions has become significantly restricted.

Will a generic Ozempic be available soon?

Not in the near term. The core U.S. composition patent on semaglutide runs until approximately December 2031. Semaglutide requires a biosimilar pathway, not a simple generic. Industry analysts project practical biosimilar entry no earlier than 2032–2033, with additional formulation patents potentially extending protection further.

Related conditions

Condition/Glp 1 Muscle Loss

Related medications

Drug/Ozempic · Drug/Wegovy Cost · Drug/Wegovy Vs Ozempic · Drug/Semaglutide · Drug/Glp 1 Agonists

Specialties

Specialty/Primary Care

Talk to a clinician

Say what's going on in your own words. Gale finds a clinician licensed in your state and shows the real cost before you book.

Find care →

When to seek care

  • —Severe abdominal pain, especially pain radiating to the back — may indicate pancreatitis
  • —Yellowing of the skin or eyes, or right-side abdominal pain — may indicate gallbladder disease
  • —Signs of a serious allergic reaction: rash, swelling of the face or throat, difficulty breathing
  • —Rapid or significant vision changes — Ozempic has been associated with worsening of diabetic retinopathy
  • —Symptoms of kidney problems: decreased urination, swelling in the legs or feet
  • —Personal or family history of medullary thyroid carcinoma or MEN 2 syndrome — Ozempic carries an FDA black box warning for thyroid C-cell tumors observed in animal studies

Call 911 or go to the nearest emergency room for severe abdominal pain, difficulty breathing, or anaphylaxis.

General health information, not medical advice. Synthetic demonstration content.

References

  1. 1.U.S. Food and Drug Administration (2017). Ozempic (semaglutide) Injection — NDA 209637 Approval Letter and Prescribing Information. FDA Center for Drug Evaluation and Research. link ✓FDA approval date (December 5, 2017), NDA number 209637, approved indication for type 2 diabetes, drug class (GLP-1 receptor agonist), active ingredient semaglutide
  2. 2.Novo Nordisk / NovoCare (2026). Ozempic Savings and Support — Ozempic.com / NovoCare Patient Assistance Program. Novo Nordisk (manufacturer). link ✓Savings card eligibility ($25/fill, commercial insurance, up to 48 months), list price (~$1,027/pen), self-pay pricing ($199/$349/$499), patient assistance program (free medication, income ≤200% FPL)
  3. 3.Abel + Imray; TradeMarkia Patent Analysis (2025). Ozempic Patent Expiry: Have the Scales Finally Tipped? / When Does the Ozempic Patent Expire?. Abel + Imray IP Newsletter; TradeMarkia. link ✓Core U.S. semaglutide composition patent term through December 2031; biosimilar entry projected 2032–2033; explains why no generic is currently available
  4. 4.Burr & Forman LLP; FDA Press Communications (2025). The FDA Removes Semaglutide from the Drug Shortage List. Burr & Forman Legal Insights; FDA.gov. link ✓FDA resolved semaglutide shortage February 2025; 503A compounding deadline April 22, 2025; 503B deadline May 22, 2025; compounded semaglutide no longer widely available
  5. 5.Doctronic / America's Fair Healthcare (2026). Ozempic Prior Authorization: How to Get Insurance Approval. Doctronic.ai; AmericasFairHealthcare.org. link ✓Prior authorization criteria (type 2 diabetes diagnosis, step therapy requirements, documentation of A1C and comorbidities); appeal success rates with clinical documentation
  6. 6.Mahaffey KW, Tuttle KR, Arici M, et al. (2024). Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. European Heart Journal. doi:10.1093/eurheartj/ehae637 ✓FLOW trial: semaglutide 1 mg reduced composite of major kidney outcomes, CV events, and death by 24% in adults with type 2 diabetes and CKD; supports expanded FDA indications beyond glycemic control

https://www.gale.care/drugs/ozempic-cost · 6 sources. General health information, not medical advice — synthetic demonstration content.